FCGR3A and Miyoshi myopathy: Moreover, in the BM of patients with MM, differential expression of surface markers of various NK cell subsets was reported, i.e., reduced expression of activating receptors, DNAX accessory molecule-1 (DNAM-1), NKG2D, CD16, and NKp44, which could contribute to attenuated antitumor response [13].